$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2017 Q3 Form 10-Q Financial Statement

#000114420417042898 Filed on August 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $200.0K $370.0K $190.0K
YoY Change 25.0% 94.74%
% of Gross Profit
Research & Development $87.73K $25.19K $18.03K
YoY Change 94.2% 39.72%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $295.0K $396.0K $208.1K
YoY Change 38.79% 90.29%
Operating Profit -$295.0K -$396.0K -$209.2K
YoY Change 38.79% 89.25%
Interest Expense $129.8K $63.24K $1.150K
YoY Change 6484.37% 5399.13%
% of Operating Profit
Other Income/Expense, Net $242.8K -$490.4K -$1.150K
YoY Change -12419.48% 42540.43%
Pretax Income -$52.18K -$886.4K -$210.0K
YoY Change -75.67% 322.07% 2000.0%
Income Tax
% Of Pretax Income
Net Earnings -$52.18K -$886.4K -$209.2K
YoY Change -75.67% 323.59% 1992.47%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$367.90 -$6.255K -$1.591K
COMMON SHARES
Basic Shares Outstanding 106.3M shares 106.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.00K $100.0K $30.00K
YoY Change -33.33% 233.33%
Cash & Equivalents $21.22K $104.4K $25.76K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.22K $100.0K $30.00K
YoY Change -36.59% 233.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $188.8K $199.6K $91.68K
YoY Change 82.79% 117.73%
TOTAL ASSETS
Total Short-Term Assets $21.22K $100.0K $30.00K
Total Long-Term Assets $188.8K $199.6K $91.68K
Total Assets $210.0K $299.6K $121.7K
YoY Change 53.58% 146.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $160.0K $53.20K $25.60K
YoY Change 256.75% 107.8% 156.03%
Accrued Expenses $10.00K $9.869K $2.736K
YoY Change 254.36% 260.71%
Deferred Revenue
YoY Change
Short-Term Debt $250.0K $270.0K $70.00K
YoY Change 108.33% 285.71% -56.25%
Long-Term Debt Due $130.0K
YoY Change
Total Short-Term Liabilities $1.270M $1.314M $304.0K
YoY Change 184.78% 332.17% 78.84%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $10.00K $70.00K
YoY Change -66.67% -85.71%
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $10.00K $10.00K $70.00K
YoY Change -66.67% -85.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.270M $1.314M $304.0K
Total Long-Term Liabilities $10.00K $10.00K $70.00K
Total Liabilities $1.280M $1.322M $373.1K
YoY Change 171.25% 254.42% 119.44%
SHAREHOLDERS EQUITY
Retained Earnings -$1.896M -$357.6K
YoY Change 430.29%
Common Stock $873.7K $106.2K
YoY Change 722.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.070M -$1.020M -$250.0K
YoY Change
Total Liabilities & Shareholders Equity $210.0K $299.6K $121.7K
YoY Change 53.58% 146.23%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$52.18K -$886.4K -$209.2K
YoY Change -75.67% 323.59% 1992.47%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change -100.0%
Cash From Operating Activities -$280.0K -$270.0K -$100.0K
YoY Change 133.33% 170.0%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K $100.0K
YoY Change -1100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $100.0K -$100.0K $0.00
YoY Change -1100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.00K 380.0K 110.0K
YoY Change -35.71% 245.45%
NET CHANGE
Cash From Operating Activities -280.0K -270.0K -100.0K
Cash From Investing Activities 100.0K -100.0K 0.000
Cash From Financing Activities 90.00K 380.0K 110.0K
Net Change In Cash -90.00K 10.00K 10.00K
YoY Change -1000.0% 0.0%
FREE CASH FLOW
Cash From Operating Activities -$280.0K -$270.0K -$100.0K
Capital Expenditures -$100.0K $100.0K
Free Cash Flow -$180.0K -$370.0K
YoY Change 38.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-766572 USD
CY2017Q2 us-gaap Management Fee Payable
ManagementFeePayable
293000 USD
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
767390 USD
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
299617 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
66385 USD
CY2017Q2 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
125000 USD
CY2016Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
100000 USD
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4879 USD
dei Trading Symbol
TradingSymbol
CELZ
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
106313750 shares
CY2016Q4 us-gaap Management Fee Payable
ManagementFeePayable
280000 USD
CY2017Q2 us-gaap Cash
Cash
104396 USD
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
106314 USD
CY2016Q4 us-gaap Cash
Cash
221868 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
105014 USD
CY2017Q2 us-gaap Assets
Assets
299617 USD
CY2016Q4 us-gaap Assets
Assets
322512 USD
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
53204 USD
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9869 USD
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-157791 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
322512 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1896279 USD
CY2017Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1022575 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
453864 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1313920 USD
CY2017Q2 us-gaap Liabilities
Liabilities
1322192 USD
us-gaap Operating Expenses
OperatingExpenses
636837 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1129707 USD
us-gaap Net Income Loss
NetIncomeLoss
-1129707 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105667617 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5423 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
503767 USD
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
106226387 shares
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Operating Expenses
OperatingExpenses
355226 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-357092 USD
us-gaap Net Income Loss
NetIncomeLoss
-357092 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87525106 shares
CY2017Q2 celz Working Capital Deficit
WorkingCapitalDeficit
1209524 USD
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
158194 USD
celz Employee Service Sharebased Compensation Nonvested Awards Expiration Period
EmployeeServiceSharebasedCompensationNonvestedAwardsExpirationPeriod
2021
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2017Q2 us-gaap Revenues
Revenues
0 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25189 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
368016 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-886356 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-886356 USD
CY2017Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2786 USD
CY2016Q2 us-gaap Revenues
Revenues
0 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18028 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
187576 USD
CY2016Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2493 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
208097 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-209247 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-209247 USD
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95589802 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
us-gaap Share Based Compensation
ShareBasedCompensation
142423 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-13181 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5754 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
13000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-493222 USD
celz Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
475750 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-117472 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221868 USD
us-gaap Interest Paid
InterestPaid
4050 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1319 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2736 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
210000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-138955 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
164617 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25662 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25762 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
5546 USD
celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
0 USD
us-gaap Stock Issued1
StockIssued1
100000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
100000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-100000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2016Q2 celz Amount Of Debt Payable At Closing
AmountOfDebtPayableAtClosing
20000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></i></b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;&#150;&#160;The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. &#160;Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
celz Class Of Warrant Or Right Conversion Ratio
ClassOfWarrantOrRightConversionRatio
one warrant to purchase another share of common stock at $0.10 per share for each ten shares purchased in the offering.
CY2017Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
44273 USD
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2017Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
104918 USD
CY2016Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
0 USD
CY2017Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
681056 USD
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2017Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
6069 USD
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
90000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
118931 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4314 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
285750 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
55941 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-427125 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
24284 USD
us-gaap Notes Assumed1
NotesAssumed1
0 USD
us-gaap Notes Assumed1
NotesAssumed1
20000 USD
CY2017Q2 celz Royalty Payment Description
RoyaltyPaymentDescription
5% from gross sales of products. StemSpine has also agreed to pay royalties of 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.
CY2017Q2 us-gaap Interest Expense
InterestExpense
63240 USD
CY2016Q2 us-gaap Interest Expense
InterestExpense
1150 USD
us-gaap Interest Expense
InterestExpense
65745 USD
us-gaap Interest Expense
InterestExpense
1866 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-490365 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1150 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-492870 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1866 USD
CY2017Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
427125 USD
CY2016Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
427125 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
140957 USD
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106313750 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105013750 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106313750 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105013750 shares
CY2017Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1949206 shares
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
50000 USD
CY2017Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
200000 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.25
CY2017Q2 celz Warrant Expiration Term
WarrantExpirationTerm
P5Y
CY2017Q2 us-gaap Share Price
SharePrice
0.45
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0086 pure
CY2017Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
389750 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
113319 USD
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1900000 shares

Files In Submission

Name View Source Status
0001144204-17-042898-index-headers.html Edgar Link pending
0001144204-17-042898-index.html Edgar Link pending
0001144204-17-042898.txt Edgar Link pending
0001144204-17-042898-xbrl.zip Edgar Link pending
celz-20170630.xml Edgar Link completed
celz-20170630.xsd Edgar Link pending
celz-20170630_cal.xml Edgar Link unprocessable
celz-20170630_def.xml Edgar Link unprocessable
celz-20170630_lab.xml Edgar Link unprocessable
celz-20170630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v472848_10q.htm Edgar Link pending
v472848_ex10-1.htm Edgar Link pending
v472848_ex31-1.htm Edgar Link pending
v472848_ex31-2.htm Edgar Link pending
v472848_ex32-1.htm Edgar Link pending
v472848_ex32-2.htm Edgar Link pending